...
首页> 外文期刊>Applied and Environmental Microbiology >Methicillin-Resistant Staphylococcus aureus Phage Plaque Size Enhancement Using Sublethal Concentrations of Antibiotics
【24h】

Methicillin-Resistant Staphylococcus aureus Phage Plaque Size Enhancement Using Sublethal Concentrations of Antibiotics

机译:使用亚致死浓度的抗生素增强耐甲氧西林金黄色葡萄球菌噬菌斑的大小

获取原文

摘要

Phage therapy presents an alternative approach against the emerging methicillin-resistant Staphylococcus aureus (MRSA) threat. Some of the problems encountered during isolation of MRSA phages include the high prevalence of enteric phages in natural sources, nonspecific absorption of viable phage, and the formation of pinpoint or tiny plaques. The phage isolated in this study, MR-5, also formed tiny plaques against its host S. aureus ATCC 43300 (MRSA), making its detection and enumeration difficult. An improved method of increasing the plaque size of MRSA phage by incorporating sublethal concentrations of three different classes of antibiotics (inhibitors of protein synthesis) in the classical double-layer agar (DLA) method was investigated. The β-lactam and quinolone antibiotics commonly employed in earlier studies for increasing the plaque size did not show any significant effect on the plaque size of isolated MR-5 phage. Linezolid (oxazolidinone class), tetracycline, and ketolide antibiotics brought significant enhancements (3 times the original size) in the plaque size of MR-5 phage. Prior treatment with these antibiotics resulted in significant reductions in the time of adsorption and the latent period of MR-5 phage. To rule out whether the action of linezolid (which brought the maximum increase in plaque size) was specific for a single phage only, its effect on the plaque size of seven other S. aureus-specific phages was also assessed. Significant enhancements in the plaque size of these phages were observed. These results indicate that this modification can therefore safely be incorporated in the traditional DLA overlay method to search for new MRSA-virulent phages.
机译:噬菌体疗法提供了一种针对正在出现的耐甲氧西林金黄色葡萄球菌(MRSA)威胁的替代方法。在分离MRSA噬菌体的过程中遇到的一些问题包括天然来源的肠道噬菌体的高流行,活噬菌体的非特异性吸收以及精确或微小噬菌斑的形成。在这项研究中分离出的噬菌体MR-5,还针对其宿主金黄色葡萄球菌ATCC 43300(MRSA)形成了微小的噬菌斑,使其难以检测和计数。研究了通过在经典双层琼脂(DLA)方法中加入亚致死浓度的三种不同类别的抗生素(蛋白质合成抑制剂)来增加MRSA噬菌体噬斑大小的改进方法。早期研究中通常用于增加噬菌斑大小的β-内酰胺和喹诺酮类抗生素对分离的MR-5噬菌体的噬菌斑大小未显示任何显着影响。利奈唑胺(恶唑烷酮类),四环素和酮内酯类抗生素使MR-5噬菌体的噬菌斑大小显着增强(原始大小的3倍)。事先用这些抗生素治疗可显着减少MR-5噬菌体的吸附时间和潜伏期。为了排除利奈唑胺的作用(最大程度增加噬菌斑大小)是否仅对单个噬菌体具有特异性,还评估了其对其他七个金黄色葡萄球菌特异性噬菌体的噬斑大小的影响。观察到这些噬菌体的噬斑大小显着增加。这些结果表明,这种修饰可以安全地并入传统的DLA覆盖方法中,以寻找新的MRSA毒力噬菌体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号